BioCentury
ARTICLE | Product Development

Dec. 13 Quick Takes: Bellus headed for Phase III in chronic cough

Plus: Veru’s Entadfi approved, Brii asset on hold and updates from Arbutus, BrainStorm and Vaccitech

December 14, 2021 1:02 AM UTC

Bellus Health Inc. (NASDAQ:BLU; TSX:BLU) is expecting to start a Phase III trial in 2H22 for BLU-5937 after the two higher doses of the P2X3 antagonist met the primary endpoint of a significant ...



Access this Article